Wolff B, Sahel J-A, Mateo-Montoya A, Mauget-Faÿsse M, Baillif S, Le Mer Y
Fondation ophtalmologique Rothschild, 25, rue Manin, 75019 Paris, France.
J Fr Ophtalmol. 2013 Jan;36(1):e5-9. doi: 10.1016/j.jfo.2012.04.004. Epub 2013 Jan 8.
Angioid streaks are biomicroscopically observable manifestations that frequently lead to choroidal neovascularization. Traditional treatments used to include laser photocoagulation or photodynamic therapy. Over the past few years, anti-VEGF therapies have been used as an alternative treatment. The case of a 54-year-old patient who received anti-VEGF therapy (ranibizumab) for the treatment of choroidal neovascularization secondary to angioid streaks is reported. The patient received two injections that led to complete resolution of intraretinal fluid and reduction in lesion size. After 1 year of follow-up, the patient has presented no recurrence. This case illustrates the efficacy of intravitreal anti-VEGF therapy for choroidal neovascularization in angioid streaks. Further prospective studies on a larger number of patients should help establish the best treatment and follow-up strategies.
血管样条纹是生物显微镜下可观察到的表现,常导致脉络膜新生血管形成。传统治疗方法过去包括激光光凝或光动力疗法。在过去几年中,抗血管内皮生长因子(VEGF)疗法已被用作替代治疗方法。本文报告了一名54岁患者,该患者接受抗VEGF疗法(雷珠单抗)治疗血管样条纹继发的脉络膜新生血管。该患者接受了两次注射,视网膜内液完全消退,病变大小减小。经过1年的随访,患者未出现复发。该病例说明了玻璃体内抗VEGF疗法治疗血管样条纹脉络膜新生血管的疗效。对更多患者进行进一步的前瞻性研究应有助于确立最佳治疗和随访策略。